Crucially, benefitting from the full OFF of the nanophotosensitizer in the bloodstream prior to its entry into tumor cells, the intravenous administration of TNP1/ZnPc does not cause noticeable skin phototoxicity or any other adverse side effects even when exposed to simulated sunlight (Figure 1C). The gene discussed is TNP1; the disease is neoplasm.